Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
May 13 2024 - 8:00AM
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of novel treatments for patients suffering
from serious hematologic diseases, announced today that company
management will participate in a fireside chat at the H.C.
Wainwright BioConnect Investor Conference on Monday, May 20th at
10:30 am ET.
A live webcast of the fireside chat will be available through
the investor relations section of the Company's website at
ir.discmedicine.com and an archived replay will be available after
the event.
About Disc
Disc Medicine (NASDAQ:IRON) is a clinical-stage
biopharmaceutical company committed to discovering, developing, and
commercializing novel treatments for patients who suffer from
serious hematologic diseases. We are building a portfolio of
innovative, potentially first-in-class therapeutic candidates that
aim to address a wide spectrum of hematologic diseases by targeting
fundamental biological pathways of red blood cell biology,
specifically heme biosynthesis and iron homeostasis. For more
information, please visit www.discmedicine.com.
Media Contact
Peg RusconiVerge Scientific
Communicationsprusconi@vergescientific.com
Investor Relations Contact
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Sep 2023 to Sep 2024